Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

ESS improves quality of life in CRS patients

Upwards of 76 percent of patients with chronic rhinosinusitis (CRS) experienced significant quality of life (QOL) improvements after undergoing endoscopic sinus surgery (ESS), according to new research in the January 2010 issue of Otolaryngology - Head and Neck Surgery.

3 Jan 2010

Kidney transplantation saves life

For more than 20 years Delores Evans battled diabetes, high blood pressure and, finally, kidney failure. By 2008 she needed a new kidney to stay alive, but she never could have imagined the circumstances that brought it about.

29 Dec 2009

Cell Therapeutics supports Code on Interactions with Healthcare Professionals

Cell Therapeutics, Inc. announced today its support of the Pharmaceutical Research Manufacturers of America's (PhRMA) "Code on Interactions with Healthcare Professionals, revised July 2008" (PhRMA Code). Adherence to the Code is voluntary for commercial biotechnology and pharmaceutical companies.

22 Dec 2009

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Response Biomedical Corporation announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a continuation of the patent entitled “Sensitive Immunochromatographic Assay”. This patent covers key aspects of Response Biomedical’s lateral flow immunoassays with the proprietary RAMP® testing platform.

21 Dec 2009

EMEA grants orphan drug designation for pixantrone in Europe

Cell Therapeutics, Inc. ("CTI") announced today that the European Medicines Agency (EMEA) has granted pixantrone orphan drug designation for the treatment of DLBCL which accounts for about 80% of aggressive non-Hodgkin's lymphoma.

21 Dec 2009

InHealth to further understand socioeconomic impact of medical devices and diagnostics

As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.

19 Dec 2009

ODAC to review Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).

17 Dec 2009

Group of drugs used to treat heart failure shows promise for fighting colon cancer

Scientists in Sweden are reporting for the first time that a group of drugs used to treat heart failure shows promise for fighting colon cancer. The study is in ACS' Journal of Natural Products, a monthly publication. Colon cancer is the third most common cancer in the United States, with more than 150,000 cases diagnosed in the U.S. each year.

17 Dec 2009

MHI launches new research program in heart failure

The Montreal Heart Institute (MHI) and its Foundation (MHIF) launched today the Carolyn and Richard J. Renaud Research Chair in Heart Failure, the first of its kind in Québec.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

VNA of Greater Philadelphia expands its home health and specialty services in Bucks County

The Visiting Nurse Association (VNA) of Greater Philadelphia is expanding its traditional home health and specialty services to patients who reside in lower Bucks County.

14 Dec 2009

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Chemotherapy generally improves survival in postmenopausal breast cancer patients, according to a landmark study led by Dr. Kathy Albain of Loyola University Health System.

11 Dec 2009

Italy's economically disadvantaged people have higher rates of hospitalization for ACSC disorders

Despite free public healthcare, Italy's poor are more likely to end up in hospital with avoidable conditions, new research shows. This pattern, reported today in the online open access journal BMC Public Health, mirrors findings from a number of different healthcare systems around the world, although to date fewer studies have been completed in Europe.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

New Acesis software platform improves patient safety and quality care

Acesis, the enterprise software company focused on healthcare performance improvement, today announced results from its first six months of service for the University of California, San Francisco (UCSF) Division of Hospital Medicine.

9 Dec 2009

Despite rising costs of U.S. health care, quality lags in ambulatory care

Most primary care physicians active in the Medicare program work in practices with too few patients to reliably measure significant differences in common measures of quality and cost performance, according to a study in the December 9 issue of JAMA.

9 Dec 2009

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.

8 Dec 2009

Updated results from phase III EXTEND clinical trial of pixantrone released

Cell Therapeutics, Inc. ("CTI") announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies.

7 Dec 2009

Congestive Heart Failure News and Research

ESS improves quality of life in CRS patients

Kidney transplantation saves life

Cell Therapeutics supports Code on Interactions with Healthcare Professionals

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

EMEA grants orphan drug designation for pixantrone in Europe

InHealth to further understand socioeconomic impact of medical devices and diagnostics

ODAC to review Cell Therapeutics' NDA for pixantrone

Group of drugs used to treat heart failure shows promise for fighting colon cancer

MHI launches new research program in heart failure

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Pfizer announces results from studies evaluating neratinib

Combination therapy improves overall survival in women with advanced breast cancer

VNA of Greater Philadelphia expands its home health and specialty services in Bucks County

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Italy's economically disadvantaged people have higher rates of hospitalization for ACSC disorders

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

New Acesis software platform improves patient safety and quality care

Despite rising costs of U.S. health care, quality lags in ambulatory care

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Updated results from phase III EXTEND clinical trial of pixantrone released

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News